Skip to main content
. Author manuscript; available in PMC: 2014 May 28.
Published in final edited form as: Arthritis Rheum. 2012 Sep;64(9):2824–2835. doi: 10.1002/art.34498

Table 1.

Demographics and baseline characteristics of randomized population (N = 755)*

IE IT SE ST
N, % of total in treatment arm 244 (32.3) 132 (17.5) 255 (33.8) 124 (16.4)
Age, years 50.7±13.4 48.8±12.7 48.6±13.0 49.3±12.0
Female 181 (74.2) 101 (76.5) 176 (69.0) 87
(70.2)
Race:    Caucasian 188 (77.1) 107 (81.1) 200 (78.4) 106 (85.5)
      African American 31 (12.7) 11 (8.3) 29 (11.4) 14 (11.3)
Ethnicity: Hispanic/Latino 26 (10.7) 17 (12.9) 32 (12.6) 10 (8.1)
Body Mass Index 29.3±7.0 30.0±8.2 30.0±6.7 29.2±7.3
Disease duration (months) 3.5±6.4 4.1±7.2 2.9±5.6 4.5±7.6
RF + 216 (88.5) 121 (91.7) 232 (91.0) 108 (87.1)
RF− and CCP+ 8 (3.3) 4(3.0) 9 (3.5) 4(3.2)
CCP−/not tested with 2 erosions 20 (8.2) 7(5.3) 14 (5.5) 12 (9.7)
Prior DMARD use 68 (27.9) 30 (22.7) 58 (22.8) 22 (17.7)
   Etanercept use** 0 0 1 (0.4) 0
   Infliximab use** 1 (0.4) 0 0 0
   Anakinra use** 1 (0.4) 0 1 (0.4) 0
   HCQ use 5 (2.1) 3 (2.3) 4(1.6) 3 (2.4)
   SSZ use 1(0.4) 0 0 1 (0.8)
   MTX use 60 (24.6) 27 (20.5) 52 (20.4) 18 (14.5)
   MTX use > 40 mg total** 3 (1.2) 1 (0.8) 3(1.2) 3(2.4)
Taking low-dose corticosteroids at screening: 105 (43.0) 58 (43.9) 111 (43.5) 41 (33.1)
  Mean dose, if corticosteroid use at screening (mg
prednisone/day)
3.4±4.3 3.4±4.2 3.4±4.3 2.6±4.1
*

Mean±SD or number of participants (%), no differences across treatment arms, all p>0.05

**

Protocol Exception/Violation

HHS Vulnerability Disclosure